Standout Papers

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials 2020 2026 2022 2024425
  1. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (2020)
    Philippe Gevaert, Theodore A. Omachi et al. Journal of Allergy and Clinical Immunology

Immediate Impact

1 from Science/Nature 27 standout
Sub-graph 1 of 11

Citing Papers

Refining the impact of genetic evidence on clinical success
2024 StandoutNature
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
2024 Standout
2 intermediate papers

Works of Lutaf Islam being referenced

Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis
2020
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
2020 Standout

Author Peers

Author Last Decade Papers Cites
Lutaf Islam 371 332 405 8 534
Derrick Kaufman 298 274 327 9 479
N. Zhang 310 280 300 7 483
Jane Gilbert 244 315 256 8 484
Dewayne T. Bradley 433 237 241 12 621
Aiko I. Klingler 414 357 365 14 587
D. Polzehl 400 253 306 8 535
Angela Treis 178 253 231 5 598
Pooja Takhar 108 389 358 6 620
Ashraf Uzzaman 51 211 179 9 506
Kennedy Dw 452 65 85 5 512

All Works

Loading papers...

Rankless by CCL
2026